InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity.
InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity.
复制标题
InCVAX - 通过光免疫疗法诱导肿瘤特异性免疫治疗晚期转移性癌症的新策略
DOI：
10.1016/j.canlet.2015.01.029
复制
发表时间：
2015-04-10
期刊：
影响因子：
9.7
通讯作者：
Chen, Wei R.
中科院分区：
文献类型：
--
作者：
Zhou, Feifan;Li, Xiaosong;Naylor, Mark F.;Hode, Tomas;Nordquist, Robert E.;Alleruzzo, Luciano;Raker, Joseph;Lam, Samuel S. K.;Du, Nan;Shi, Lei;Wang, Xiuli;Chen, Wei R.
关键词：
提出了一种新颖的、有前途的潜在癌症疫苗策略，即对实体瘤使用两次注射程序，以促使免疫系统识别并系统地消除原发性和转移性癌症。两次注射程序包括在选定的肿瘤上进行局部光热应用，旨在释放全细胞肿瘤抗原，然后局部注射由半合成功能化葡萄糖胺聚合物、N-二氢半乳糖壳聚糖（GC）组成的免疫佐剂，旨在激活抗原呈递细胞并促进增加肿瘤抗原的摄取。因此，该策略被提议作为原位自体癌症疫苗（inCVAX），它可以激活抗原呈递细胞并将其原位暴露于肿瘤抗原，目的是诱导全身性肿瘤特异性T细胞反应。在此，系统回顾了过去几十年来inCVAX用于治疗转移性癌症的进展。还讨论了局部光热治疗和 GC 免疫刺激的抗肿瘤免疫反应。这种治疗方法通常也称为激光免疫疗法（LIT）。
A novel, promising potential cancer vaccine strategy was proposed to use a two-injection procedure for solid tumors to prompt the immune system to identify and systemically eliminate the primary and metastatic cancers. The two-injection procedure consists of local photothermal application on a selected tumor intended to liberate whole cell tumor antigens, followed by a local injection of an immunoadjuvant that consists of a semi-synthetic functionalized glucosamine polymer, N-dihydro-galacto-chitosan (GC), which is intended to activate antigen presenting cells and facilitate an increased uptake of tumor antigens. This strategy is thus proposed as an in situ autologous cancer vaccine (inCVAX) that may activate antigen presenting cells and expose them to tumor antigens in situ, with the intention of inducing a systemic tumor specific T-cell response. Here, the development of inCVAX for the treatment of metastatic cancers in the past decades are systematically reviewed. The antitumor immune responses of local photothermal treatment and immunological stimulation with GC are also discussed. This treatment approach is also commonly referred to as laser immunotherapy (LIT).
登录
查看更多内容
影响因子：
2.1
作者：
Chen, WR;Liu, H;Nordquist, RE
通讯作者：
Nordquist, RE
DOI：
10.1615/jenvironpatholtoxicoloncol.v25.i1-2.180
发表时间：
2006-01-01
影响因子：
2.4
作者：
Chen, WR;Huang, Z;Liu, H
通讯作者：
Liu, H
影响因子：
6.4
作者：
Chen, WR;Jeong, SW;Nordquist, RE
通讯作者：
Nordquist, RE
DOI：
10.1007/978-1-4419-1603-7_10
发表时间：
2009-01-01
期刊：
LIPID A IN CANCER THERAPY
影响因子：
--
作者：
Cluff, Christopher W.
通讯作者：
Cluff, Christopher W.
DOI：
10.3390/molecules16108504
发表时间：
2011-10-11
期刊：
Molecules (Basel, Switzerland)
影响因子：
--
作者：
Chung YC;Yeh JY;Tsai CF
通讯作者：
Tsai CF